Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer (Q34096234): Difference between revisions

From Wikidata

Jump to navigation Jump to search

Browse history interactively

← Older edit Newer edit →

Revision as of 00:15, 15 July 2024

scientific article published on April 26, 2010

Language	Label	Description	Also known as
English	Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer	scientific article published on April 26, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Ingo Bauerfeind

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dirk Elling

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Volker Heinemann

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20847831

15 July 2024

publication date

26 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

full work available at URL

https://www.karger.com/Article/Pdf/285775

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847831

15 July 2024

https://europepmc.org/articles/PMC2931095

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847831

15 July 2024

https://europepmc.org/articles/PMC2931095?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847831

15 July 2024

https://doi.org/10.1159/000285775

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847831

15 July 2024

http://www.karger.com/Article/Pdf/285775

0 references

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

s1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

13-15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Breast cancer. Clinical practice guidelines in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

Estrogen-receptor biology: continuing progress and therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

Aromatase inhibitors for breast cancer: lessons from the laboratory

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

5 July 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

28 October 2018

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931095

28 October 2018

The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20847831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://pubmed.ncbi.nlm.nih.gov/20847831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1159/000285775

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

release_7rbp4cmjojcala2kase3rxfzyq

1 reference

https://api.fatcat.wiki/v0/release/7rbp4cmjojcala2kase3rxfzyq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34096234&oldid=2204563644"

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.

Alternative Proxies:

Alternative Proxy